ARROW muyedzo, Genentech, NSCLC, pralsetinib
Pralsetinib inotenderwa neFDA kune isiri-diki cell kenza yemapapu ine RET gene fusions.
Nyamavhuvhu 2023: Pralsetinib (Gavreto, Genentech, Inc.) yakapihwa mvumo nguva dzose neFood and Drug Administration yevarwere vakuru vane metastatic RET fusion-positive isiri diki cell lung cancer (NSCLC), sekutemerwa neFDA.
CD20, Columbi, DLBCL, Genentech
Glofitamab-gxbm inotenderwa neFDA kune yakasarudzwa yakadzokororwa kana refractory yakakura B-cell lymphomas.
Chikunguru 2023: The Food and Drug Administration yakapa kukurumidza kubvumidza glofitamab-gxbm (Columvi, Genentech, Inc.) yekudzokorodza kana refractory diffuse hombe B-cell lymphoma, isina kutsanangurwa neimwe nzira (DLBCL, NOS) kana hombe B-cell ..
Genentech, Lunsumio, mosunetuzumab-axgb, inoratidzira follicular lymphoma
Mosunetuzumab-axgb inopihwa kukurumidza kubvumidzwa kwekudzokazve kana refractory follicular lymphoma.
Ndira 2023: Mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), bispecific CD20-inotungamirwa CD3 T-cell inobata kune varwere vakura vane kudzoka kana refractory follicular lymphoma (FL) inotevera maviri kana anopfuura kutenderera kwe systemic therapy, rece.
alveolar nyoro chikamu sarcoma, Atezolizumab, central nerve system, Genentech, Tecentriq
Atezolizumab inotenderwa neFDA kune alveolar soft tissue sarcoma
Zvita 2022: Atezolizumab (Tecentriq, Genentech, Inc.) yakatenderwa neChikafu neDrug Administration (FDA) yevakuru nevana varwere vane unrectable kana metastatic alveolar soft part sarcoma vane makore maviri e…
Burkitt lymphoma, Burkitt-kufanana lymphoma, DLBCL, Genentech, Rituxan, Rituximab
Rituximab pamwe nechemotherapy inotenderwa neFDA kune zviratidzo zvegomarara revana
Kurume 2022: Chikafu neDrug Administration yakabvumidza rituximab (Rituxan, Genentech, Inc.) pamwe chete nechemotherapy yeCD20-positive diffuse hombe B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma.
Atezolizumab, Genentech, NSCLC, Tecentriq, Ventana Medical Systems, VENTANA PD-L1
Atezolizumab inotenderwa neFDA seadjuvant kurapwa kune isiri-diki cell kenza yemapapu.
Nov 2021: Chikafu neDrug Administration yakabvumidza atezolizumab (Tecentriq, Genentech, Inc.) yekurapa adjuvant muvarwere vane nhanho II kusvika IIIA isiri-diki cell cancer yemapapu (NSCLC) ine mapundu ane PD-L1 kutaura o.